Jorge Abarca

Jorge Abarca

Auto-generated profile, based on publicly available information

Jorge Abarca

Infectious Diseases, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center, Muscat, Sultanate of Oman

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2024 in IJID Regions
Verified
Journal Article
Open access
BABASSEM Ibrahim AWADA
BASSEM Ibrahim AWADA
AZAref Zribi
Aref Zribi
AGAhmad Ghoche
Ahmad Ghoche
HAHasan Al-Sayegh
Hasan Al-Sayegh
MMManyando Milupi
Manyando Milupi
JAJorge Abarca
Jorge Abarca
Candida species frequently cause bloodstream infections; however, there is a lack of epidemiological studies on candidemia in Oman. To address this, we conducted a retrospective study at Sultan Qaboos Comprehensive Cancer and Research Center from October 2021 to October 2023. Our study identified 27 episodes of candidemia among 26 patients with cancer, with an incidence of 4.9 per 1000 admissions. Non-albicans Candida (NAC) prevailed over C. albicans (70.37% vs 29.62%), with C. glabrata as the predominant NAC species (n = 10; 37%). The 30-day mortality rate was 40.7%, showing no significant difference between NAC and C. albicans but was notably higher in critically ill patients (P = 0.03). In Oman, NAC surpasses C. albicans as a causative pathogen for candidemia with a high mortality rate.

2 July 2024 in IJID Regions
Verified
Journal Article
Open access
BABASSEM Ibrahim AWADA
BASSEM Ibrahim AWADA
JAJorge Abarca
Jorge Abarca
SMSumbel Mumtaz
Sumbel Mumtaz
AAAthar Al-Khirbash
Athar Al-Khirbash
HAHasan Al-Sayegh
Hasan Al-Sayegh
GVGeorge M Varghese
George M Varghese
Objectives: This study aimed to delineate the characteristics and outcomes of gram-negative bacteremia (GNB) in oncology patients; analyze the risk factors for multi-drug–resistant (MDR) GNB; and assess its impact on the recurrence of bloodstream infection (BSI), hospital stay, and 30-day mortality. Methods: Data, including demographics, clinical features, common cancers, and microbiologic findings, were collected retrospectively from electronic medical records of patients admitted with solid tumors and BSI episodes between January and December 2022. Fisher's exact tests were used to determine the effect of MDR-GNB on 30-day mortality and BSI recurrence. The Wilcoxon rank-sum test assessed the differences in the length of hospital stay. Logistic regression models identified the risk factors for MDR-GNB. Results: Among 1074 patients, 77 episodes of GNB bacteremia occurred in 59 individuals (47% male, median age 57.4 years). Of these, 37 (48%) were MDR-GNB. Carbapenem resistance was noted in 9.1% of GNB episodes. Previous antibiotic use was significantly associated with MDR-GNB (odds ratio 7.82; 95% confidence interval 2.52-24). MDR-GNB was linked to longer hospital stays (median 23 vs 10.5 days, P = 0.003) and higher recurrence rates than non-MDR-GNB (35.13% vs 5.0%, P <0.001). However, 30-day mortality did not significantly differ between the groups (35.14% vs 32.5%, P = 0.81). Conclusion: Previous antibiotic use predicted MDR-GNB in patients with solid tumor. MDR-GNB bacteremia increased the length of hospital stay and risk of recurrence compared with non-MDR-GNB bacteremia.